Table 5. Thirty days clinical outcome.

	All patients	23mm	26mm	29mm	P-Value
Number of patients, N	235	77	91	67
Early safety endpoint at 30 days	19 (8.1%)	6 (7.8%)	7 (7.7%)	6 (8.9%)	0.95
All-cause mortality	6 (2.6%)	3 (3.9%)	2 (2.2%)	1 (1.5%)	0.64
Stroke disabling and non-disabling	5 (2.1%)	2 (2.6%)	1 (1.1%)	2 (2.9%)	0.68
Acute kidney injury—stage 2/3	5 (2.1%)	1 (1.3%)	3 (3.3%)	1 (1.5%)	0.59
Major vascular complication	7 (3.0%)	1 (1.3%)	5 (5.5%)	1 (1.5%)	0.22
Valve dysfunction requiring a repeat procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	—
Endocarditis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	—
Valve thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	—
Myocardial infarction	0	0	0	0	—
Implantation of covered stent	10 (4.3%)	2 (2.6%)	6 (6.6%)	2 (2.9%)	0.36
Surgical repair	0	0	0	0	—
Pacemaker implantation*	21 (8.9%)	7 (9.1%)	6 (6.6%)	8 (11.9%)	0.45

Values are mean ± SD or n (%).

* Indication for pacemaker based on second degree (type II) or third degree atrioventricular block